Neither work in any appreciable way, in fact, both effectively shut down the immune system and allow for secondary infections (highly likely) as well as liver complication and malignancies.

https://www.covid19treatmentguidelines.nih.go...nhibitors/

Quote:

---

Recommendation
The Panel recommends against the use of anti-IL-6 receptor monoclonal antibodies (e.g., sarilumab, tocilizumab) or anti-IL-6 monoclonal antibody (siltuximab) for the treatment of COVID-19, except in a clinical trial (BI).
Rationale
Preliminary, unpublished data from randomized, controlled trials failed to demonstrate efficacy of sarilumab or tocilizumab in patients with COVID-19. There are only limited, unpublished data describing the efficacy of siltuximab in patients with COVID-19.11

---

The UK is taking a page from the US and just approving anything to try to keep the sheep calm. Disgusting.

Quote:

---

The UK government is working closely with the manufacturer, to ensure the drugs - tocilizumab and sarilumab - continue to be available to UK patients.

---